Trial · NCT03100344
Adverse events120
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 120
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Placebo | 12 | 56 | |
| other | Nasopharyngitis | Infections and infestations | Nemolizumab (10 mg) | 18 | 55 | |
| other | Nasopharyngitis | Infections and infestations | Nemolizumab (30 mg) | 14 | 57 | |
| other | Nasopharyngitis | Infections and infestations | Nemolizumab (90 mg) | 13 | 57 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 1 | 56 | |
| other | Upper respiratory tract infection | Infections and infestations | Nemolizumab (10 mg) | 4 | 55 | |
| other | Upper respiratory tract infection | Infections and infestations | Nemolizumab (30 mg) | 6 | 57 | |
| other | Upper respiratory tract infection | Infections and infestations | Nemolizumab (90 mg) | 4 | 57 | |
| other | Sinusitis | Infections and infestations | Placebo | 0 | 56 | |
| other | Sinusitis | Infections and infestations | Nemolizumab (10 mg) | 4 | 55 | |
| other | Sinusitis | Infections and infestations | Nemolizumab (30 mg) | 3 | 57 | |
| other | Sinusitis | Infections and infestations | Nemolizumab (90 mg) | 1 | 57 | |
| other | Gastroenteritis | Infections and infestations | Placebo | 1 | 56 | |
| other | Gastroenteritis | Infections and infestations | Nemolizumab (10 mg) | 0 | 55 | |
| other | Gastroenteritis | Infections and infestations | Nemolizumab (30 mg) | 3 | 57 | |
| other | Gastroenteritis | Infections and infestations | Nemolizumab (90 mg) | 4 | 57 | |
| other | Oral herpes | Infections and infestations | Placebo | 1 | 56 | |
| other | Oral herpes | Infections and infestations | Nemolizumab (10 mg) | 2 | 55 | |
| other | Oral herpes | Infections and infestations | Nemolizumab (30 mg) | 1 | 57 | |
| other | Oral herpes | Infections and infestations | Nemolizumab (90 mg) | 3 | 57 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03100344/events